Acquired mechanisms of immune escape in cancer following immunotherapy.

Genome Med

Authors	J Bryan Iorgulescu David Braun Giacomo Oliveira Derin Keskin Catherine Wu
Keywords	Humans Neoplasms Antigen Presentation Immunotherapy Tumor Escape
Abstract	Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pressures: selecting cancer subclones deficient in antigenicity and/or immunogenicity, thereby facilitating immune escape.
Year of Publication	2018
Journal	Genome Med
Volume	10
Issue	1
Pages	87
Date Published	2018 Nov 22
ISSN	1756-994X
DOI	10.1186/s13073-018-0598-2
PubMed ID	30466478
PubMed Central ID	PMC6249768
Links	DOI Google Scholar PubMed
Grant list	T32 HL-116324 / CA / NCI NIH HHS / United States P50 CA101942 / CA / NCI NIH HHS / United States R21 CA216772-01A1 / CA / NCI NIH HHS / United States R01 HL103532 / HL / NHLBI NIH HHS / United States T32 HL116324 / HL / NHLBI NIH HHS / United States R21 CA216772 / CA / NCI NIH HHS / United States R01 CA155010 / CA / NCI NIH HHS / United States 1RO1CA155010-02 / CA / NCI NIH HHS / United States 5T32H7627 / HL / NHLBI NIH HHS / United States

Recent Broad Publications